Trial 9403: Baseline Characteristics
description
Transcript of Trial 9403: Baseline Characteristics
Trial 9403: Baseline CharacteristicsDemographic ParameterDemographic Parameter
PlaceboPlacebo(N = 84)(N = 84)
MemantineMemantine(N = 82)(N = 82)
MMSEMMSE
Mean Mean SD SD 6.1 6.1 2.8 2.8 6.5 6.5 2.6 2.6
Min, MaxMin, Max 0, 90, 9 0, 90, 9
HISHIS
Mean Mean SD SD 5.7 5.7 3.2 3.2 5.2 5.2 2.9 2.9
Min, MaxMin, Max 1, 121, 12 1, 121, 12
BGP care dependencyBGP care dependency
Mean Mean SD SD 21.8 21.8 7.7 7.7 21.3 21.3 7.6 7.6
BGP cognitiveBGP cognitive
Mean Mean SD SD 5.4 5.4 2.5 2.5 5.5 5.5 2.6 2.6
Trial 9403: Baseline Characteristics by HIS Score
Demographic Demographic ParameterParameter
HIS HIS ≤ 4 (AD)≤ 4 (AD) HIS > 4 (VaD)HIS > 4 (VaD)PlaceboPlacebo(N = 38)(N = 38)
MemantineMemantine(N = 41)(N = 41)
PlaceboPlacebo(N = 46)(N = 46)
MemantineMemantine(N = 41)(N = 41)
MMSEMMSE
Mean Mean SD SD 6.8 6.8 2.4 2.4 6.7 6.7 2.6 2.6 5.5 5.5 3.0 3.0 6.4 6.4 2.8 2.8
Min, MaxMin, Max 1, 91, 9 0, 90, 9 0, 90, 9 0, 90, 9
HISHIS
Mean Mean SD SD 2.7 2.7 1.1 1.1 2.9 2.9 1.0 1.0 8.1 8.1 2.2 2.2 7.6 7.6 2.1 2.1
Min, MaxMin, Max 1, 41, 4 1, 41, 4 5, 125, 12 5, 125, 12
BGP care dependencyBGP care dependency
Mean Mean SD SD 19.0 19.0 7.63 7.63 20.8 20.8 6.75 6.75 23.1 23.1 7.21 7.21 20.8 20.8 8.32 8.32
BGP cognitiveBGP cognitive
Mean Mean SD SD 4.6 4.6 2.72 2.72 5.1 5.1 2.62 2.62 5.6 5.6 2.23 2.23 5.3 5.3 2.62 2.62
Trial 9403: FDA Defined AD Subpopulation (LOCF)
PlaceboPlaceboN = 25N = 25
MemantineMemantineN = 38N = 38 M-PM-P
MeanMean SDSD MeanMean SDSD p-valuep-value
BGP-CareBGP-CareDependencyDependency -1.92-1.92 4.004.00 -6.39-6.39 5.725.72 0.0020.002
BGP-CogBGP-Cog -0.64-0.64 1.321.32 -2.16-2.16 2.012.01 0.0020.002
CGI-CCGI-C 3.723.72 0.680.68 3.053.05 0.770.77 < 0.001< 0.001
Trial 9403: Change from Baseline in BGP Care Dependency: VaD Subpopulation (HIS > 4)HIS > 4)
PlaceboPlacebo MemantineMemantine
p-value*p-value*NN MeanMean SDSD NN MeanMean SDSD
Endpoint Endpoint (LOCF)(LOCF) 4646 -3.7-3.7 5.635.63 4141 -4.8-4.8 4.744.74 0.3650.365
Week 12 Week 12 (OC)(OC) 4343 -4.0-4.0 5.595.59 3939 -5.1-5.1 4.734.73 0.3340.334
* Wilcoxon rank sum test (stratified by center)
ADCS-ADL19 Item Analyses Item Points Item Points
Eating 0-4 Find personal belongings 0-3
Walking 0-3 Obtain a beverage 0-3
Toileting 0-3 Dispose of garbage appropriately
0-3*
Bathing 0-3 Travel beyond home 0-4
Grooming 0-3 Left on own 0-3
Dressing 0-4 Run water for washing without help
0-1
Using a telephone 0-5 Turn off water after using without help 0-1
Watching television 0-3 Turn on a light when entering a dark area 0-1
Attend to conversation 0-3 Turn off light when leaving or going to sleep 0-1*
Clear dishes after meal/snack 0-3
*p< .10
Trial 9605: ADCS-ADL19: Cumulative Percentage of Patients Completing 28 Weeks of Treatment
0
10
20
30
40
50
60
70
80
90
100
-10 -5 0 5 10 15 20 25
ADCS-ADL Change from Baseline
Cum
ulat
ive
Perc
enta
ge
Placebo
Memantine
Trial 9605: Severe Impairment Battery: Cumulative Percentage of Patients Completing 28 Weeks of Treatment
0
10
20
30
40
50
60
70
80
90
100
-15 -10 -5 0 5 10 15 20 25 30
SIB Change from Baseline
Cum
ulat
ive
Perc
enta
ge
Placebo
Memantine
Trial 9605: RUD
Residential StatusResidential StatusPlacebo Placebo
N = 76 (%)N = 76 (%)MemantineMemantineN = 90 (%)N = 90 (%) p-value*p-value*
BaselineBaseline
InstitutionInstitution 1313 77 .16.16
End pointEnd point
InstitutionInstitution 1818 88 .04.04
* Chi-square testBased on the TTP subset at week 28.Community = patient’s own home or friend’s/relative’s home. Institution = intermediate care facility, home oriented towards dementia care, or other long-term care facility.
Institutionalization
ADCS-ADL19 Item Analyses Item Points Item Points
Eating 0-4 Find personal belongings 0-3*
Walking 0-3 Obtain a beverage 0-3
Toileting 0-3 Dispose of garbage appropriately
0-3
Bathing 0-3 Travel beyond home 0-4
Grooming 0-3** Left on own 0-3
Dressing 0-4 Run water for washing without help
0-1
Using a telephone 0-5 Turn off water after using without help 0-1
Watching television 0-3* Turn on a light when entering a dark area 0-1
Attend to conversation 0-3* Turn off light when leaving or going to sleep 0-1
Clear dishes after meal/snack 0-3
*p < .10; **p < 0.01
Trial MD-02: NPIp = 0.002
p < 0.001
p = 0.010
Impr
ovem
ent
Wor
seni
ng
Treatment Week
-4.0
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
4.0
0 12 24 End Point
Mea
n (S
EM) C
hang
e Fr
om B
asel
ine
Memantine/donepezilPlacebo/donepezil
Trial MD-02: CIBIC+ Subgroup Analyses
SubgroupPlaceboPlacebo MemantineMemantine
p-valuep-valueNN MeanMean MedianMedian SDSD NN MeanMean MedianMedian SDSD
MMSE ≤ 9 72 4.90 5 1.10 89 4.67 5 1.03 0.035
MMSE > 9 124 4.52 4 0.99 109 4.19 4 1.01 0.121
MMSE ≤ 10 93 4.91 5 1.05 104 4.63 5 1.03 0.004
MMSE > 10 103 4.43 4 1.00 94 4.17 4 1.02 0.403
Van Elteren test.
PCS Vital Sign Values – Criteria
Vital Sign ParameterVital Sign Parameter Observed ValueObserved ValueChange Relative to Change Relative to BaselineBaseline
Systolic Blood PressureSystolic Blood Pressure 180 mm Hg180 mm Hg Increase of Increase of 20 20 90 mm Hg90 mm Hg Decrease of Decrease of 20 20
Diastolic Blood PressureDiastolic Blood Pressure 105 mm Hg105 mm Hg Increase of Increase of 15 15 50 mm Hg50 mm Hg Decrease of Decrease of 15 15
PulsePulse 120 bpm120 bpm Increase of Increase of 15 15 50 bpm50 bpm Decrease of Decrease of 15 15
WeightWeightAnyAny Increase of Increase of 7% 7%AnyAny Decrease of Decrease of 7% 7%
Mean Change in Blood Pressure
PlaceboPlacebo(N = 604)(N = 604)
n (%)n (%)
MemantineMemantine(N = 606)(N = 606)
n (%)n (%)Diastolic Blood Pressure (mm Hg)Diastolic Blood Pressure (mm Hg)
Baseline, mean (SD)Baseline, mean (SD) 78.0 (9.9)78.0 (9.9) 78.1 (10.2)78.1 (10.2)Change From Baseline, mean (SD)Change From Baseline, mean (SD) -0.7 (9.2)-0.7 (9.2) -0.4 (10.2)-0.4 (10.2)Systolic Blood Pressure (mm Hg)Systolic Blood Pressure (mm Hg)Baseline, mean (SD)Baseline, mean (SD) 136.6 (16.6)136.6 (16.6) 138.0 (16.5)138.0 (16.5)Change From Baseline, mean (SD)Change From Baseline, mean (SD) -0.8 (17.0)-0.8 (17.0) -1.0 (16.6)-1.0 (16.6)
Double-Blind, Placebo-Controlled Dementia TrialsDouble-Blind, Placebo-Controlled Dementia Trials
NMDA Receptor Antagonist-Related Neuropathology Membrane bound cytoplasmic vacuoles within the
first day of dosing Vacuoles are dilated endoplasmic reticulum
and Golgi in neurons of cingulate, retrosplenial cortex
Visualization requires aldehyde perfusion Not observed in frozen or immersion fixed
brain tissue Neuronal vacuolization progresses to necrosis
in proportion of neurons, 2+ days after NMDA antagonist exposure
NMDA Antagonist Neuropathology Rodent specific Class effect of NMDA antagonists Not observed in primates at doses inducing
significant clinical signs Clinical relevance unknown
Memantine Neuropathologyis Rodent Specific Neuropathology only observed in rats and at
doses 12 or more times the MRHD(on a mg/m2 basis)
Neuropathology observed at doses 2-4x’s higher than ataxia
Neuropathology not observed in non-rodent species In dogs at dose which causes seizure and death In baboons at doses which cause significant
clinical signs
MRHD = maximum recommended human dose, 20 mg/day.MRHD = maximum recommended human dose, 20 mg/day.
Efficacy in MMSE Subpopulation:< 10, 5-9 and ≥ 10 – CIBIC+
-1
-0.9
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0∆ < 10 ∆ 5-9 ∆ ≥ 10
Trial 9605Trial MD-02
p = 0.462
p = 0.180
p = 0.093
p = 0.035
p = 0.030
p = 0.121
Functional Activities Staging (FAST)1. No difficulties, either subjectively or objectively2. Complains of forgetting locations of objects; subjective work
difficulties3. Decreased job functioning evident to coworkers; difficulty in
traveling to new locations; decreased organizational capacity4. Decreased ability to perform complex tasks5. Requires assistance in choosing proper clothing6. (a) Difficulty putting clothing on properly
(b) Unable to bathe properly; may develop fear of bathing(c) Inability to handle mechanics of toileting(d) Urinary incontinence(e) Fecal incontinence
7. (a ) Ability to speak limited (1 to 5 words a day)(b) All intelligible vocabulary lost (c) Nonambulatory(d) Unable to sit up independently (e) Unable to smile(f) Unable to hold up head up
9605
ADCS-ADL19 Items Item Item PointsPoints ItemItem PointsPoints
EatingEating 0-40-4 Find personal belongingsFind personal belongings 0-30-3
Walking Walking 0-30-3 Obtain a beverageObtain a beverage 0-30-3
ToiletingToileting 0-30-3 Dispose of garbage Dispose of garbage appropriatelyappropriately 0-30-3
BathingBathing 0-30-3 Travel beyond homeTravel beyond home 0-40-4
GroomingGrooming 0-30-3 Left on ownLeft on own 0-30-3
DressingDressing 0-40-4 Run water for washing Run water for washing without helpwithout help 0-10-1
Using a telephoneUsing a telephone 0-50-5 Turn off water after using Turn off water after using without helpwithout help 0-10-1
Watching televisionWatching television 0-30-3 Turn on a light when entering Turn on a light when entering a dark areaa dark area 0-10-1
Attend to Attend to conversationconversation 0-30-3 Turn off light when leaving or Turn off light when leaving or
going to sleepgoing to sleep 0-10-1
Clear dishes after Clear dishes after meal/snackmeal/snack 0-30-3
ADCS-ADL19 Item Selection Criteria Used ADCS subjects with MMSE 0-15 50% of sample was able to do item (score > 0) Item Kappa ≥ 0.4 for test-retest reliability Item showed sufficient stepwise scaling
Compared performance/nonperformance ratios across MMSE scores
Decline ≥ 0.2 points at 12-months Cronbach’s alpha > 0.80 for total score
Galasko et al submitted
ADCS-ADL19 Item Formats Items 1-6
Regarding grooming, in the past 4 weeks, which best describes {S} optimal performance?
3 = cleaned and cut fingernails without physical help 2 = brushed and combed hair without physical help 1 = kept face and hands clean without physical help 0 = needed help for grooming of hair, face, hands, and fingernails
Items 7-15 In the past 4 weeks, did {S} dispose of garbage or litter in an appropriate place or
container at home? 0 = No 0 = Don’t know
If Yes; which best describes how {S} usually performed: 3 = without supervision or help 2 = with supervision 1 = with physical help
Items 16-19 In the past 4 weeks, did {S} usually turn off the faucet after finishing running water
without help? 1 = Yes 0 = No
ADCS-ADL19 Reliability Test-retest reliability
ADCS data, N = 145 MMSE 0-15, M = 7.3 ± 4.7 (Galasko et al submitted) 1-month: Kappa = 0.93 2-month: Kappa = 0.89
9605 (placebo group) 1-month: ICC = 0.92
MD-02 (placebo group) 1-month: ICC = 0.92 2-month: ICC = 0.92
Internal Consistency (Cronbach’s alpha) 9605 baseline placebo data = 0.92 MD-02 baseline placebo data = 0.92
SIB Concurrent Validity Correlations 100 pt version
Baseline correlations (ADCS; Schmitt et al 1997) MMSE = 0.83 CDR = -0.65; Sum of boxes = -0.75;
GDS = -0.68, FAST = -0.59 12-month change score correlations (ADCS; Schmitt et al 1997)
CDR = -0.25; Sum of boxes = -0.38;GDS = -0.19, FAST = -0.25
Baseline correlations (9605 placebo subjects) ADCS-ADL19 = 0.63; CIBIC (K-Tau) = -0.18;
NPI = 0.10; FAST = -0.40 Baseline correlations (MD-02 placebo subjects)
ADCS-ADL19 = 0.58; CIBIC (K-Tau) = -0.20;NPI = -0.29; FAST = -0.50
152 pt version; MMSE 0-13 (Saxton et al 1990) MMSE = 0.74
133 pt version; MMSE 0-13 (Saxton et al 1993) MMSE = 0.76; Mattis DRS = 0.88
BGP Scale Description
Comprehensive geriatric symptomatology rating scale Developed for nurses administration in geriatric settings
Beoordelingsschaal vor Oudere Patienten (BOP) Beurteilungsskala fur geriatrische Patienten (BGP) “Rating Scale for Geriatric Patients”
Based on Stockton Geriatric Rating Scale (Meer and Baker, 1966)
Lower scores = greater function (35 items, 0-2 points) Areas include
Aggressiveness, disability, disorientation, depression, inactivity, impaired communication, ADL impairment
Items primarily rated “never,” “sometimes,” or “often”
BGP Care Dependency3. Requires assistance with eating4. The patient is urinary or feces incontinent at
daytime10. The patient makes himself understood (by
speaking, writing, or gestures)11. The patient finds his way in the nursing home
(e.g., to his room, to the toilet, to his/her place at the table) [around the house]
12. The patient understands in what home or clinic he is [where he/she lives]
13. The patient knows the names of the staff [of family members and close friends]
14. The patient understands what you communicate to him (by speaking, writing, or gestures)
17. The patient reacts when being called by his name18. The patient keeps self occupied in useful
activities out of therapeutic activities (e.g., working, reading, playing games, hobbies, talking to others)
20. The patient socializes to one or several other patients [friends]
21. The patient urinates or defecates in inappropriate places
22. The patient helps other residents [family members/friends] on his own initiative (e.g., moving the wheelchair, passing items)
23. The patient is cooperative to do what is asked25. The patient always repeats the same movements of no
use (e.g., walking to and fro, toddling back and forth, wringing hands, and
26. The patient makes sounds which are directed to no one27. The patient enters into a conversation on his own
initiative28. The patient is allowed to go out30. The patient drowses during the daytime [takes naps
during the day]31. The patient requires assistance with dressing32. The patient is urinary or feces incontinent at night33. A special support is required to prevent the patient
from falling out of bed34. The patient disturbs other residents at night35. The patient is restless at night
Italic text= Cognitive subscaleBracketed text indicate changes for MD-02
Treatment Duration
Double-Blind Double-Blind Open-LabelOpen-LabelMemantineMemantine(N = 856)(N = 856)
TotalTotalMemantineMemantine(N = 1357)(N = 1357)
Placebo Placebo (N = 922)(N = 922)
MemantineMemantine(N = 940)(N = 940)
Treatment Duration, n (%)Treatment Duration, n (%)
4 weeks (28 days) 4 weeks (28 days) 884 (95.9) 884 (95.9) 896 (95.4) 896 (95.4) 835 (97.5) 835 (97.5) 1306 (96.3) 1306 (96.3)
12 weeks (84 days) 12 weeks (84 days) 802 (87.0) 802 (87.0) 818 (87.1) 818 (87.1) 778 (90.9) 778 (90.9) 1202 (88.6) 1202 (88.6)
24 weeks (168 days) 24 weeks (168 days) 553 (60.0) 553 (60.0) 584 (62.2) 584 (62.2) 506 (59.1) 506 (59.1) 862 (63.6) 862 (63.6)
36 weeks (252 days) 36 weeks (252 days) 0 0 0 0 42 (4.9) 42 (4.9) 429 (31.6) 429 (31.6)
48 weeks (336 days) 48 weeks (336 days) 0 0 0 0 37 (4.3) 37 (4.3) 387 (28.5) 387 (28.5)
Core Dementia Trials
Dosing Scheme – Double-Blind Phase
Previous Previous TreatmentTreatment
Memantine Titration Memantine Titration GroupGroup Week 1Week 1 Week 2Week 2 Week 3Week 3
PlaceboPlacebo
Group AGroup AAMAM 00 5 mg/day5 mg/day 5 mg/day5 mg/day
PMPM 5 mg/day5 mg/day 5 mg/day5 mg/day 10 mg/day10 mg/day
Group BGroup BAMAM 00 00 00
PMPM 5 mg/day5 mg/day 10 mg/day10 mg/day 15 mg/day15 mg/day
Group CGroup CAMAM 5 mg/day5 mg/day 10 mg/day10 mg/day 10 mg/day10 mg/day
PMPM 5 mg/day5 mg/day 10 mg/day10 mg/day 10 mg/day10 mg/day
Group DGroup DAMAM 00 00 00
PMPM 10 mg/day10 mg/day 20 mg/day20 mg/day 20 mg/day20 mg/day
MemantineMemantineGroup EGroup E
AMAM 10 mg/day10 mg/day 10 mg/day10 mg/day 10 mg/day10 mg/day
PMPM 10 mg/day10 mg/day 10 mg/day10 mg/day 10 mg/day10 mg/day
Group FGroup FAMAM 00 00 00
PMPM 20 mg/day20 mg/day 20 mg/day20 mg/day 20 mg/day20 mg/day
Ongoing Trials – MD-03
Patient Populations
Trial GroupsTrial Groups
Treatment GroupsTreatment GroupsEstimated Memantine Estimated Memantine First Time ExposureFirst Time Exposure
Estimated Placebo/Estimated Placebo/Active ControlActive Control
Total Enrolled per Total Enrolled per TrialTrial
Trials in Dementia PopulationTrials in Dementia PopulationMEM-MD-01 155155 155155 310310MEM-MD-10 155155 155155 310310MEM-MD-12 216216 216216 432432MRZ-90001-9901 3939 1111 5050IE2101†† 8282 4141 12312399679 9494 4747 14114199817 55 55 1010MEM-MD-03 237237 00 475475MEM-MD-11 6565 00 129129MRZ-90001-9708 100100 00 100100IE2901 109109 00 109109MRZ-90001-9408/3 OLEX 00‡‡ 00 105105
Ongoing Trials
Agitation - MMSE <10
Agitation - MMSE >=10
Urinary Incontinence - MMSE <10
Urinary Incontinence - MMSE >=10
Fall - MMSE <10
Fall - MMSE >=10
Headache - MMSE <10
Headache - MMSE >= 10
Dizziness - MMSE <10
Dizziness - MMSE >= 10
Adverse Events (Reported by >5% Patients in the Memantine Group)Trials 9605 and MD-02 Combination (Moderate to Severe AD Patients) (1 of 2)
AE Preferred Term RR (95% CI’s) RR (95% CI)
Decrease Increase
.5 1 5 >10
0.66 (0.38, 1.16)
0.41 (0.21, 0.82)
1.20 (0.53, 2.74)
1.07 (0.45, 2.53)
0.93 (0.39, 2.21)
1.16 (0.51, 2.62)
2.55 (0.89, 7.33)
2.92 (0.76, 11.20)
1.66 (0.48, 5.79)
0.99 (0.46, 2.12)